You are here
Articles
Posted on Friday, March 15, 2013 - 4:59pm
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
Posted on Thursday, March 14, 2013 - 11:28am
CML Stem Cell Burden at Diagnosis Associated With Treatment Outcomes
By Dave Levitan
March 11, 2013
Laboratory studies have suggested that chronic myeloid leukemia (CML) stem cells are resistant to...
Posted on Wednesday, March 13, 2013 - 1:12pm
Oncology Enters Era of Genomics: Sledge Calls for Overhaul of Clinical Trials System
Anita T. Shaffer
Posted on Sunday, March 10, 2013 - 3:11pm
Definitions, methodological and statistical issues for phase 3 clinical trials in
chronic myeloid leukemia: a proposal by the European LeukemiaNet
Joelle Guilhot,1 Michele Baccarani,2 Richard E. Clark,3...
Posted on Sunday, March 10, 2013 - 3:03pm
Suboptimal Responses in Chronic Myeloid Leukemia
Elias Jabbour, MD,1 Giuseppe Saglio, MD, PhD,2 Timothy P Hughes, MD,3 and Hagop Kantarjian, MD1
Abstract
The high response rates and increased survival associated with...
Posted on Wednesday, March 6, 2013 - 1:52pm
Susan Branford 1,2
1 Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide,
Australia; and 2 University of Adelaide, Adelaide, Australia
Monitoring response...
Posted on Wednesday, March 6, 2013 - 1:50pm
David T. Yeung 1-3 and Susan Branford 1,3
Posted on Wednesday, March 6, 2013 - 1:45pm
David Marin
Hammersmith Hospital, Imperial College London, London, United Kingdom.
Posted on Saturday, March 2, 2013 - 3:29pm
"...Three months ago, my PCR result was .07% (or 0.0245% on the IS). It doesn’t take a genius (I wish it literally did take a genius) to see that the results aren’t as good as they were three months ago. However, it’s...
Posted on Thursday, February 28, 2013 - 12:31pm
“Borne Out of Necessity and Data”: Conquering Mutations in Leukemia
By Jessica Wapner
'A couple of months ago, the FDA approved the latest drug to treat chronic myeloid leukemia (CML). Called ponatinib (brand name...
Posted on Wednesday, February 27, 2013 - 9:29pm
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G. Chapuis1,*, Gunnar B. Ragnarsson1,*,†, Hieu N. Nguyen1, Colette N. Chaney1,...
Posted on Friday, February 22, 2013 - 9:02pm
'Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD'
Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney K. Stewart, Lauren E. Damon, Sara...
Posted on Wednesday, February 6, 2013 - 12:07pm
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Pratap Neelakantan1, Gareth Gerrard1, Claire Lucas2, Dragana Milojkovic1, Philippa May1...
Posted on Monday, February 4, 2013 - 1:58pm
The findings are published in the Dec. 24 online early edition of the Proceedings of the National Academy of Sciences (PNAS).
Posted on Saturday, January 26, 2013 - 8:10pm
The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
- ‹ previous
- 12 of 29
- next ›